Brief: Orchard Therapeutics And Sirion Biotech Announce Licensing Agreement
14/12/2018 12:35
Dec 14 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS AND SIRION BIOTECH ANNOUNCE LICENSING
AGREEMENT TO ENHANCE GENE THERAPY MANUFACTURING EFFICIENCY
* ORCHARD THERAPEUTICS PLC - SIRION WILL BE ENTITLED TO
UPFRONT
AND MILESTONE PAYMENTS
* ORCHARD THERAPEUTICS PLC - SIRION IS ELIGIBLE TO RECEIVE
ROYALTIES ON NET SALES OF FUTURE PRODUCTS THAT UTILIZE
LENTIBOOST TECHNOLOGY.
* ORCHARD THERAPEUTICS - UNDER TERMS OF AGREEMENT, SIRION
WILL
PROVIDE CO WITH LICENSE TO ITS PROPRIETARY LENTIVIRAL
TRANSDUCTION ENHANCER LENTIBOOST
Source text for Eikon: ID:nGNX7ydDt1
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln